Positive opinion moves crizotinib closer to approval in Japan
This article was originally published in Scrip
Executive Summary
The latest batch of new products to receive positive opinions in Japan includes Pfizer's Xalkori (crizotinib), for the treatment of non-small cell lung cancer.